Inscrição na biblioteca: Guest
Critical Reviews™ in Immunology

Publicou 6 edições por ano

ISSN Imprimir: 1040-8401

ISSN On-line: 2162-6472

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.3 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.6 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00079 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.24 SJR: 0.429 SNIP: 0.287 CiteScore™:: 2.7 H-Index: 81

Indexed in

Immunological Effects of Thalidomide and Its Chemical and Functional Analogs

Volume 22, Edição 5-6, 2002, 14 pages
DOI: 10.1615/CritRevImmunol.v22.i5-6.40
Get accessGet access

RESUMO

Thalidomide has recently shown considerable promise in the treatment of a number of conditions, such as leprosy and cancer. Its effectiveness in the clinic has been ascribed to wide-ranging properties, including anti-TNF-a, T-cell costimulatory and antiangiogenic activity. Novel compounds with improved immunomodulatory activity and side effect profiles are also being evaluated. These include selective cytokine inhibitory drugs (SelCIDsTM), with greatly improved TNF-a inhibitory activity, and immunomodulatory drugs (IMiDsTM) that are structural analogs of thalidomide, with improved properties. A third group recently identified within the SelCID group, with phosphodiesterase type 4–independent activity, is in the process of being characterized in laboratory studies. This review describes the emerging immunological properties of thalidomide, from a historical context to present-day clinical applications, most notably in multiple myeloma but also in other cancers, inflammatory disease, and HIV. We also describe the laboratory studies that have led to the characterization and development of SelCIDs and IMiDs into potentially clinically relevant drugs. Early trial data suggest that these novel immunomodulatory compounds may supercede thalidomide to become established therapies, particularly in certain cancers. Further evidence is required, however, to correlate the clinical efficacy of these compounds with their known immunomodulatory, antiangiogenic, and antitumor properties.

CITADO POR
  1. Lehman Thomas J.A., Schechter Sharon J., Sundel Robert P., Oliveira Sheila K., Huttenlocher Anna, Onel Karen B., Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study, The Journal of Pediatrics, 145, 6, 2004. Crossref

  2. Briones Javier, Emerging therapies for B-cell non-Hodgkin lymphoma, Expert Review of Anticancer Therapy, 9, 9, 2009. Crossref

  3. Amato Robert J., Sarao Harmeet, A Phase I Study of Paclitaxel/Doxorubicin/Thalidomide in Patients with Androgen-Independent Prostate Cancer, Clinical Genitourinary Cancer, 4, 4, 2006. Crossref

  4. Adams Alexa, Lehman Thomas J.A, Update on the pathogenesis and treatment of systemic onset juvenile rheumatoid arthritis, Current Opinion in Rheumatology, 17, 5, 2005. Crossref

  5. DePianta Robert, Douville Kenneth, Nickerson Beverly, Borjas Ricardo E., Chiral Screening Methods for Pharmaceutical Analysis and Purification in an Industrial Laboratory, in Chiral Separation Methods for Pharmaceutical and Biotechnological Products, 2010. Crossref

  6. Yasui Kozo, Uchida Noriko, Akazawa Yohei, Nakamura Shinichi, Minami Isaki, Amano Yoshiro, Yamazaki Takashi, Thalidomide for treatment of intestinal involvement of juvenile-onset Behçet disease, Inflammatory Bowel Diseases, 14, 3, 2008. Crossref

  7. Chanan-Khan Asher, Porter Carl W, Immunomodulating drugs for chronic lymphocytic leukaemia, The Lancet Oncology, 7, 6, 2006. Crossref

  8. Kim Kyung-Jo, Update on the Treatment of Intestinal Behçet's Disease, Journal of Rheumatic Diseases, 21, 4, 2014. Crossref

  9. Yasui Kozo, Yashiro Masato, Tsuge Mitsuru, Manki Akira, Takemoto Kei, Yamamoto Michiko, Morishima Tsuneo, Thalidomide dramatically improves the symptoms of early-onset Sarcoidosis/Blau syndrome: Its possible action and mechanism, Arthritis & Rheumatism, 62, 1, 2010. Crossref

  10. Bruno Benedetto, Rotta Marcello, Giaccone Luisa, Massaia Massimo, Bertola Alessandra, Palumbo Antonio, Boccadoro Mario, New drugs for treatment of multiple myeloma, The Lancet Oncology, 5, 7, 2004. Crossref

  11. Liu Yi, Li Hui, Matsui Osamu, The antiangiogenic effect of thalidomide on occult liver metastases: Anin vivostudy in mice, Journal of Gastroenterology and Hepatology, 24, 6, 2009. Crossref

  12. García-Carrasco Mario, Fuentes-Alexandro Salvador, Escárcega Ricardo O., Rojas-Rodriguez Jorge, Escobar Luis E., Efficacité de la thalidomide dans les arthrites chroniques juvéniles à début systémique, Revue du Rhumatisme, 74, 9, 2007. Crossref

  13. Diamanti Antonella, Capriati Teresa, Papadatou Bronislava, Knafelz Daniela, Bracci Fiammetta, Corsetti Tiziana, Elia Domenica, Torre Giuliano, The clinical implications of thalidomide in inflammatory bowel diseases, Expert Review of Clinical Immunology, 11, 6, 2015. Crossref

  14. García-Carrasco Mario, Fuentes-Alexandro Salvador, Escárcega Ricardo O., Rojas-Rodriguez Jorge, Escobar Luis E., Efficacy of thalidomide in systemic onset juvenile rheumatoid arthritis, Joint Bone Spine, 74, 5, 2007. Crossref

  15. Longo R., Cacciamani F., Naso G., Gasparini G., Pancreatic cancer: From molecular signature to target therapy, Critical Reviews in Oncology/Hematology, 68, 3, 2008. Crossref

  16. Molica Stefano, Immunomodulatory drugs in chronic lymphocytic leukemia: A new treatment paradigm, Leukemia & Lymphoma, 48, 5, 2007. Crossref

  17. Guirgis Adel A., Zahran Magdy A.H., Mohamed Amr S., Talaat Roba M., Abdou Bishoy Y., Agwa Hussein S., Effect of thalidomide dithiocarbamate analogs on the intercellular adhesion molecule-1 expression, International Immunopharmacology, 10, 7, 2010. Crossref

  18. Chang Julie E., Kahl Brad S., Current Status of Targeted Therapies for Mantle Cell Lymphoma, Drugs, 71, 17, 2011. Crossref

  19. Puzik Alexander, Thiel Annette, Faust Kirstin, Härtel Christoph, Thalidomide has anti-inflammatory properties in neonatal immune cells, Innate Immunity, 19, 1, 2013. Crossref

  20. Maini R, Kv Patil, Mg Rainey, De Villiers F, Prj Ames, Fatal Cerebral Toxoplasmosis in a Heavily Immune Suppressed Patient with Waldentrom's Disease, Scottish Medical Journal, 53, 4, 2008. Crossref

  21. Kuriakose Philip, Targeted Therapy for Hematologic Malignancies, Cancer Control, 12, 2, 2005. Crossref

  22. Chng Wee Joo, Lau Lee Gong, Yusof Noorainun, Mow Benjamin M. F., Targeted Therapy in Multiple Myeloma, Cancer Control, 12, 2, 2005. Crossref

  23. López-Relaño Juan, Martín-Adrados Beatriz, Real-Arévalo Irene, Lozano-Bartolomé Javier, Abós Beatriz, Sánchez-Ramón Silvia, Alonso Bárbara, Gómez del Moral Manuel, Martínez-Naves Eduardo, Monocyte-Derived Dendritic Cells Differentiated in the Presence of Lenalidomide Display a Semi-Mature Phenotype, Enhanced Phagocytic Capacity, and Th1 Polarization Capability, Frontiers in Immunology, 9, 2018. Crossref

  24. Zhou Li, Verma Amit, Targeting Signal Transduction Pathways in Hematopoietic Disorders, in Molecular Basis of Hematopoiesis, 2009. Crossref

  25. Palladino Michael A., Bahjat Frances Rena, Theodorakis Emmanuel A., Moldawer Lyle L., Anti-TNF-α therapies: the next generation, Nature Reviews Drug Discovery, 2, 9, 2003. Crossref

  26. Riess Hanno, Antiangiogenic Strategies in Pancreatic Cancer, in Pancreatic Cancer, 177, 2008. Crossref

  27. Badros Ashraf, Thalidomide in Patients with Relapsed Multiple Myeloma, in Myeloma Therapy, 2008. Crossref

  28. de Fraia Pinto Livia, Compri Cecília Melleti, Fornari João Victor, Bartchewsky Waldemar, Cintra Dennys Eduardo, Trevisan Miriam, de Oliveira Carvalho Patrícia, Ribeiro Marcelo Lima, Velloso Licio A., Saad Mario J., Pedrazzoli José, Gambero Alessandra, The immunosuppressant drug, thalidomide, improves hepatic alterations induced by a high-fat diet in mice, Liver International, 30, 4, 2010. Crossref

  29. Girolamo Francesco, Coppola Cristiana, Ribatti Domenico, Trojano Maria, Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis, Acta Neuropathologica Communications, 2, 1, 2014. Crossref

  30. Hernandez-Ilizaliturri Francisco J., Reddy Nishitha, Holkova Beata, Ottman Edris, Czuczman Myron S., Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model, Clinical Cancer Research, 11, 16, 2005. Crossref

  31. Hwang Sung Hee, Rait Antonina, Pirollo Kathleen F., Zhou Qi, Yenugonda Venkata Mahidhar, Chinigo Gary M., Brown Milton L., Chang Esther H., Tumor-targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue, Molecular Cancer Therapeutics, 7, 3, 2008. Crossref

Próximos artigos

Identification of a novel five-gene prognostic model for laryngeal cancer associated with mitophagy using integrated bioinformatics analysis and experimental verification Dong Song, Lun Dong, Mei Wang, Xiaoping Gao Function of steroid receptor coactivators (SRCs) in T cells and cancers: Implications for cancer immunotherapy Wencan Zhang, Xu Cao, Hongmin Wu, Xiancai Zhong, Yun Shi, Zuoming Sun Electroacupuncture Alleviates Ischemic Stroke by Activating the mTOR/SREBP1 Pathway Jiawang Lang, Jianchang Luo, Luodan Wang, Wenbin Xu, Jie Jia, Zhipeng Zhao, Boxu Lang KIAA1429 induces the m6A modification of LINC01106 to enhance the malignancy of lung adenocarcinoma cell via JAK/STAT3 pathway Di Xu, Ziming Wang, Fajiu Li Effect of p-estrogen receptor at serine on its function and breast growth Yuan Liang, Junhui Qin, Tiancheng Ma, Tong Yang, Zhenyu Ke, Ruian Wang Mechanistic Insights into Tanshinone IIA in the Amelioration of Post-Thyroidectomy Hypoparathyroidism Xiaoyu Qian, Lin Li, Liang Chen, Chao Shen, Jian Tang MiRNA let-7d-5p alleviates inflammatory responses by targeting Map3k1 and inactivating ERK/p38 MAPK signaling in microglia Fan Fang, Cheng Chen Role of Natural Killer Cells as Cell-Based Immunotherapy in Oral Tumor Eradication and Differentiation Both In Vivo and In Vitro Kawaljit Kaur, Anahid Jewett The Current and Future States of Natural Killer Cell-Based Immunotherapy in Hepatocellular Carcinoma Tu Nguyen, Po-Chun Chen, Janet Pham, Kawaljit Kaur, Steven Raman, Anahid Jewett, Jason Chiang Phillygenin alleviated arthritis through the inhibition of NLRP3 inflammasome and Ferroptosis by AMPK Jianghui Wang, Shufang Ni, Kai Zheng, Yan Zhao, peihong zhang, Hong Chang The value of systemic immune-inflammation index and T cell subsets in the severity and prognosis of sepsis Hao Zhou Efficacy and Nuances of Precision Molecular Engineering for Hodgkin's Disease to a Gene Therapeutic Approach Muhammad Imran Qadir, Bilal Ahmed, Nadir Hussain Serum interleukin 6 and ferritin levels are the independent risk factors for pneumonia in elderly patients Hao Yuan, Jing Tian, Lu Wen Exploration of diagnostic markers associated with inflammation in chronic kidney disease (CKD) based on WGCNA and machine learning Qianjia Wu, Yang Yang, Chongze Lin Clinical significance of serum CTRP3 level in the prediction of cardiac dysfunction and intestinal mucosal barrier dysfunction in patients with severe acute pancreatitis Qiang Shao, Lin Sun The protective effect and mechanism of mild hypothermia on pig lung injury after cardiopulmonary resuscitation Jinlin Ren, Fangfang Zhu, Dongdong Sang, Mulin Cong, Shujuan Jiang Exploring mechanism of Zilongjin in treating lung adenocarcinoma based on network pharmacology combined with experimental verification Kang Zhang, Xiaoqun Chen Gastric Cancer Immune Subtypes and Prognostic Modeling: Insights from Aging-Related Genes Analysis Jian Shen, Minzhe Li Effects of different doses of dexmedetomidine on the prevention of postoperative sleep disturbance and serum neurotransmitter level in patients under general anesthesia Huifei Lu, Fei He, Ying Huang, Zhongliang Wei Identification of key ubiquitination-related genes and their associated with immune infiltration in osteoarthritis based on mRNA-miRNA network Dalu Yuan, Hailiang Shen, Lina Bai, Menglin Li, Qiujie Ye Diagnostic and Prognostic value of peripheral neutrophil CD64 index in elderly patients with community-acquired pneumonia Yan Li, Jing Zhang, Suhang Wang, Jie Cao Identification of Metabolism-Related Prognostic Biomarkers and Immune Features of Head and Neck Squamous Cell Carcinoma Rongjin Zhou, Junguo Wang Downregulation of miR-503-5p promotes the development of pancreatic cancer via targeting cyclin E2 Fei Li, Ying-pei Ling, Pan Wang, Shi-cheng Gu, Hao Jiang, Jie Zhu
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa Políticas de preços e assinaturas Begell House Contato Language English 中文 Русский Português German French Spain